… biotech company, has taken a significant step in advancing treatments … drug, PSIL-006. Unlike traditional psychedelics, this pharmaceutical … trials and, potentially, FDA approval. If successful, the drug … , chief medical officer at Delix Therapeutics, explained …

… trial to further study the safety and efficacy of the treatment. “The FDA … in two phase 3 clinical trials. In the studies, patients … FDA, by not approving the treatment, would be signaling to drug … for future drugs. Mark Rus, CEO of Delix Therapeutics Mark …

… -001, Delix CMO Dr. Aaron Koenig told Pharmaceutical Technology. Upon … biotech will take the small molecule into two planned trials … data, which demonstrated that treatment with DLX-001 does … the drug’s effects can be maintained after treatment discontinuation. …

… neuroplastogen for hearing loss treatment. Delix is pursuing the … its ongoing Phase 1 trial evaluating the safety, tolerability … phenotypic drug discovery engine to generate distinct compounds, Delix … bring patients FDA-approved, take-home medicines that will …

… an ongoing Phase 1 trial evaluating DLX-001, … of DLX-001 on antidepressant, structural, and functional … phenotypic drug discovery engine to generate distinct compounds, Delix … medicines that will serve several unmet needs and enhance the psychiatric treatment …

… Drug Abuse to advance its novel, non-hallucinogenic neuroplastogen for treatment … intramuscularly. NIH has awarded Delix Therapeutics $320K in grant … hallucinogenic properties and administration limitations,” Delix Chief Scientific Officer Kurt Rasmussen …

… adverse effects. His biotech startup, Delix Therapeutics, has … Stanford University School of Medicine investigators Dr. Boris … Drugs,” tightened regulations and disappointing clinical trials. Psychedelic drugs … a treatment for PTSD, based on clinical trial …

… uncover more effective treatments for the medical management of substance … from its Phase 1 trial evaluating the safety, … a proprietary phenotypic drug discovery engine, Delix seeks to bring … bring patients FDA-approved, take-home medicines that will …

… potential to shift the treatment paradigm for several … of the Regenerative Medicine Division at Shire Pharmaceuticals. Earlier on … had rapid and enduring antidepressant-like effects after a … from our phenotypic drug discovery engine, Delix’s seeks to …

… Medical School in Germany. He’s been researching psychedelic drugs … also co-founder of Delix Therapeutics, a biotech company that’s … and the complexity of the treatment. If we don’t … results seen in some clinical trials with psychedelics. Dölen: Learning …